Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Contributions of Gut Bacteria and Diet to Drug Pharmacokinetics in the Treatment of Parkinson's Disease
Sebastiaan P. van Kessel, Sahar El Aidy
Frontiers in Neurology (2019) Vol. 10
Open Access | Times Cited: 43

Showing 1-25 of 43 citing articles:

Mechanisms of peripheral levodopa resistance in Parkinson’s disease
Milan Beckers, Bastiaan R. Bloem, Marcel M. Verbeek
npj Parkinson s Disease (2022) Vol. 8, Iss. 1
Open Access | Times Cited: 70
Are We What We Eat? Impact of Diet on the Gut–Brain Axis in Parkinson’s Disease
Margherita Alfonsetti, Vanessa Castelli, Michele d’Angelo
Nutrients (2022) Vol. 14, Iss. 2, pp. 380-380
Open Access | Times Cited: 43
Levodopa: From Biological Significance to Continuous Monitoring
David Probst, Kartheek Batchu, John R. Younce, et al.
ACS Sensors (2024) Vol. 9, Iss. 8, pp. 3828-3839
Closed Access | Times Cited: 10
Pharmacomicrobiomics: a new field contributing to optimizing drug therapy in Parkinson’s disease
Yi Zhang, Chengjun Mo, Penghui Ai, et al.
Gut Microbes (2025) Vol. 17, Iss. 1
Open Access | Times Cited: 1
Show Me What You Have Inside—The Complex Interplay between SIBO and Multiple Medical Conditions—A Systematic Review
Natalia Sroka, Alicja Rydzewska–Rosołowska, Katarzyna Kakareko, et al.
Nutrients (2022) Vol. 15, Iss. 1, pp. 90-90
Open Access | Times Cited: 36
Oral and intestinal dysbiosis in Parkinson's disease
E. Berthouzoz, Vladimir Lazarević, Alkisti Zekeridou, et al.
Revue Neurologique (2023) Vol. 179, Iss. 9, pp. 937-946
Open Access | Times Cited: 19
The critical role of gut-brain axis microbiome in mental disorders
Kimia Basiji, Azadeh Aghamohammadi Sendani, Shaghayegh Baradaran Ghavami, et al.
Metabolic Brain Disease (2023) Vol. 38, Iss. 8, pp. 2547-2561
Closed Access | Times Cited: 18
The Gut Microbiota in Parkinson Disease: Interactions with Drugs and Potential for Therapeutic Applications
Elisa Menozzi, Anthony H.V. Schapira
CNS Drugs (2024) Vol. 38, Iss. 5, pp. 315-331
Open Access | Times Cited: 7
Parkinson’s Disease Medication Alters Small Intestinal Motility and Microbiota Composition in Healthy Rats
Sebastiaan P. van Kessel, Amber Bullock, Gertjan van Dijk, et al.
mSystems (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 26
To restrict or not to restrict? Practical considerations for optimizing dietary protein interactions on levodopa absorption in Parkinson’s disease
Carley Rusch, R. J. Flanagan, Hong‐Won Suh, et al.
npj Parkinson s Disease (2023) Vol. 9, Iss. 1
Open Access | Times Cited: 15
Small Intestinal Bacterial Overgrowth (SIBO) and Twelve Groups of Related Diseases—Current State of Knowledge
Paulina Roszkowska, Emilia Klimczak, Ewa Ostrycharz, et al.
Biomedicines (2024) Vol. 12, Iss. 5, pp. 1030-1030
Open Access | Times Cited: 5
Food supplement vitamins, minerals, amino-acids, fatty acids, phenolic and alkaloid-based substances: An overview of their interaction with drugs
Maria Lopes, Manuel A. Coimbra, Maria do Céu Costa, et al.
Critical Reviews in Food Science and Nutrition (2021) Vol. 63, Iss. 19, pp. 4106-4140
Closed Access | Times Cited: 31
Gut bacterial tyrosine decarboxylase associates with clinical variables in a longitudinal cohort study of Parkinsons disease
Sebastiaan P. van Kessel, Petri Auvinen, Filip Scheperjans, et al.
npj Parkinson s Disease (2021) Vol. 7, Iss. 1
Open Access | Times Cited: 27
Mediterranean Diet Adherence, Gut Microbiota and Parkinson’s Disease: A Systematic Review
Bibi Aliya Seelarbokus, Elisa Menozzi, Anthony H.V. Schapira, et al.
Nutrients (2024) Vol. 16, Iss. 14, pp. 2181-2181
Open Access | Times Cited: 4
Therapeutic Strategies to Treat or Prevent Off Episodes in Adults with Parkinson’s Disease
Nirosen Vijiaratnam, Thomas Foltynie
Drugs (2020) Vol. 80, Iss. 8, pp. 775-796
Closed Access | Times Cited: 29
Effects of a probiotic suspension Symprove™ on a rat early-stage Parkinson’s disease model
Marco Sancandi, Carmen De, Neringa Cypaite, et al.
Frontiers in Aging Neuroscience (2023) Vol. 14
Open Access | Times Cited: 10
Engineering the Microbiome to Prevent Adverse Events: Challenges and Opportunities
Saad Khan, Ruth Hauptman, Libusha Kelly
The Annual Review of Pharmacology and Toxicology (2020) Vol. 61, Iss. 1, pp. 159-179
Open Access | Times Cited: 27
Small Intestinal Bacterial Overgrowth as Potential Therapeutic Target in Parkinson’s Disease
Adela Dănău, Laura Dumitrescu, Antonia Lefter, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 21, pp. 11663-11663
Open Access | Times Cited: 21
Gastrointestinal Dysfunction in Parkinson’s Disease
Delaram Safarpour, Kaveh Sharzehi, Ronald F. Pfeiffer
Drugs (2022) Vol. 82, Iss. 2, pp. 169-197
Closed Access | Times Cited: 15
Management of dysphagia and gastroparesis in Parkinson’s disease in real-world clinical practice – Balancing pharmacological and non-pharmacological approaches
Roongroj Bhidayasiri, Warongporn Phuenpathom, Ai Huey Tan, et al.
Frontiers in Aging Neuroscience (2022) Vol. 14
Open Access | Times Cited: 14
Development of a reproducible small intestinal microbiota model and its integration into the SHIME®-system, a dynamic in vitro gut model
Stef Deyaert, Frédéric Moens, Walter Pirovano, et al.
Frontiers in Microbiology (2023) Vol. 13
Open Access | Times Cited: 8
Should “on-demand” treatments for Parkinson’s disease OFF episodes be used earlier?
Stuart Isaacson, Fernando Pagán, Mark Lew, et al.
Clinical Parkinsonism & Related Disorders (2022) Vol. 7, pp. 100161-100161
Open Access | Times Cited: 11
Gut Microbes in Parkinson's Disease
Anastasia Markidi, Joshua D. Elford, Celia R. Berkers, et al.
Elsevier eBooks (2024), pp. 217-240
Closed Access | Times Cited: 2
Long-term safety, tolerability and efficacy of apomorphine sublingual film in patients with Parkinson’s disease complicated by OFF episodes: a phase 3, open-label study
Jan Kassubek, Stewart A. Factor, Ernest Balaguer, et al.
Journal of Neurology (2024) Vol. 271, Iss. 6, pp. 3554-3570
Open Access | Times Cited: 2
Modulation of the Microbiome in Parkinson’s Disease: Diet, Drug, Stool Transplant, and Beyond
Ethan Brown, Samuel M. Goldman
Neurotherapeutics (2020) Vol. 17, Iss. 4, pp. 1406-1417
Open Access | Times Cited: 18
Page 1 - Next Page

Scroll to top